Institute of Respiratory Disease, Department Translational Biomedicine and Neuroscience, University "Aldo Moro", Bari, Italy.
Respiratory Disease Department, "Di Venere" Hospital, Bari, Italy.
Pulm Pharmacol Ther. 2023 Dec;83:102270. doi: 10.1016/j.pupt.2023.102270. Epub 2023 Nov 24.
Inhaled corticosteroids, along with beta2-agonists and anti-muscarinics, represent the cornerstone of asthma treatment. Although the advent of monoclonal antibodies has dramatically changed severe asthma management, there are still patients ineligible or with poor response to biologics. Moreover, high costs associated with monoclonal antibodies prescription are still an open issue, leading clinicians to carefully assess cost-benefit ratio before their administration. From this perspective, the use of single-inhaler Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium in patients with severe asthma could not only improve their clinical and functional performance, but also postpone biologic prescription, with positive repercussions on healthcare costs.
吸入性皮质类固醇，联合β2-激动剂和抗毒蕈碱药物，是哮喘治疗的基石。虽然单克隆抗体的出现极大地改变了重度哮喘的管理方式，但仍有一些患者不符合生物制剂治疗的条件或对其反应不佳。此外，与单克隆抗体处方相关的高昂费用仍然是一个悬而未决的问题，这促使临床医生在使用之前仔细评估成本效益比。从这个角度来看，在重度哮喘患者中使用倍氯米松/福莫特罗/格隆溴铵单药吸入剂不仅可以改善他们的临床和功能表现，还可以延缓生物制剂的处方，对医疗保健费用产生积极影响。
